{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:53:31Z","timestamp":1775026411179,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-024-06155-3","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T01:38:43Z","timestamp":1735609123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Validation of prognostic models in elderly patients with diffuse large B-cell lymphoma in a real-world nationwide population-based study \u2013 development of a clinical nomogram"],"prefix":"10.1007","author":[{"given":"Jelena","family":"Jelicic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Juul-Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoran","family":"Bukumiric","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikkel","family":"Runason Simonsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rasmus Rask","family":"Kragh J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Roost Clausen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Ludvigsen Al-Mashhadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Schou Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Bj\u00f8rn Poulsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Ortved Gang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarec Christoffer","family":"El-Galaly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Stauffer Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"6155_CR1","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1080\/17474086.2019.1660159","volume":"12","author":"RA Harkins","year":"2019","unstructured":"Harkins RA, Chang A, Patel SP et al (2019) Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma. Expert Rev Hematol 12:959\u2013973","journal-title":"Expert Rev Hematol"},{"key":"6155_CR2","doi-asserted-by":"crossref","unstructured":"Sehn LH, Salles G (2021) Diffuse large B-cell lymphoma. N Engl J Med 384:842\u2013858","DOI":"10.1056\/NEJMra2027612"},{"key":"6155_CR3","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.3109\/10428194.2015.1010078","volume":"56","author":"AO Gang","year":"2015","unstructured":"Gang AO, Pedersen M, d\u2019Amore F et al (2015) A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry. Leuk Lymphoma 56:2556\u20132562","journal-title":"Leuk Lymphoma"},{"key":"6155_CR4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","volume":"12","author":"F Peyrade","year":"2011","unstructured":"Peyrade F, Jardin F, Thieblemont C et al (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 12:460\u2013468","journal-title":"Lancet Oncol"},{"key":"6155_CR5","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Van Hoof A, Sebban C et al (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude Des Lymphomes De l\u2019Adulte. J Clin Oncol 23:4117\u20134126","journal-title":"J Clin Oncol"},{"key":"6155_CR6","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"MA Shipp","year":"1993","unstructured":"Shipp MA et al (1993) A predictive model for aggressive non-hodgkin\u2019s lymphoma. The international non-Hodgkin\u2019s lymphoma prognostic factors project. N Engl J Med 329:987\u2013994","journal-title":"N Engl J Med"},{"key":"6155_CR7","doi-asserted-by":"publisher","first-page":"e102594","DOI":"10.1371\/journal.pone.0102594","volume":"9","author":"V Proch\u00e1zka","year":"2014","unstructured":"Proch\u00e1zka V, Pytl\u00edk R, Jan\u00edkov\u00e1 A et al (2014) A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent. PLoS ONE 9:e102594","journal-title":"PLoS ONE"},{"key":"6155_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1365-2141.2010.08331.x","volume":"151","author":"RH Advani","year":"2010","unstructured":"Advani RH, Chen H, Habermann TM et al (2010) Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol 151:143\u2013151","journal-title":"Br J Haematol"},{"key":"6155_CR9","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M et al (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857\u20131861","journal-title":"Blood"},{"key":"6155_CR10","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bjh.13116","volume":"168","author":"T Melchardt","year":"2015","unstructured":"Melchardt T, Troppan K, Weiss L et al (2015) A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and \u03b22 -microglobulin. Br J Haematol 168:239\u2013245","journal-title":"Br J Haematol"},{"key":"6155_CR11","first-page":"46","volume":"70","author":"M Candelaria","year":"2018","unstructured":"Candelaria M, Reynoso-Nover\u00f3n N, Ponce M et al (2018) A prognostic score for survival in patients older than 65 years with diffuse large B-cell lymphoma. Rev Invest Clin 70:46\u201352","journal-title":"Rev Invest Clin"},{"key":"6155_CR12","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1634\/theoncologist.2016-0260","volume":"22","author":"K Miura","year":"2017","unstructured":"Miura K, Konishi J, Miyake T et al (2017) A host-dependent prognostic model for elderly patients with diffuse large B-cell lymphoma. Oncologist 22:554\u2013560","journal-title":"Oncologist"},{"key":"6155_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00277-017-3170-z","volume":"97","author":"D Antic","year":"2018","unstructured":"Antic D, Jelicic J, Trajkovic G et al (2018) Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities. Ann Hematol 97:267\u2013276","journal-title":"Ann Hematol"},{"key":"6155_CR14","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1634\/theoncologist.2017-0361","volume":"23","author":"H Liu","year":"2018","unstructured":"Liu H, Zhang C-L, Feng R et al (2018) Validation and refinement of the age, comorbidities, and albumin index in elderly patients with diffuse large B-cell lymphoma: an effective tool for comprehensive geriatric assessment. Oncologist 23:722\u2013729","journal-title":"Oncologist"},{"key":"6155_CR15","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/ajh.25107","volume":"93","author":"E Pardal","year":"2018","unstructured":"Pardal E, D\u00edez Baeza E, Salas Q et al (2018) A new prognostic model identifies patients aged 80 years and older with diffuse large B-cell lymphoma who may benefit from curative treatment: a multicenter, retrospective analysis by the Spanish GELTAMO group. Am J Hematol 93:867\u2013873","journal-title":"Am J Hematol"},{"key":"6155_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","volume":"21","author":"EW Steyerberg","year":"2010","unstructured":"Steyerberg EW, Vickers AJ, Cook NR et al (2010) Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 21:128\u2013138","journal-title":"Epidemiology"},{"key":"6155_CR17","doi-asserted-by":"publisher","unstructured":"Arboe B, El-Galaly TC, Clausen MR et al (2016) The danish national lymphoma registry: coverage and data quality. PLoS ONE 11. https:\/\/doi.org\/10.1371\/journal.pone.0157999","DOI":"10.1371\/journal.pone.0157999"},{"key":"6155_CR18","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133067. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"6155_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579\u2013586. https:\/\/doi.org\/10.1200\/JCO.2006.09.2403","journal-title":"J Clin Oncol"},{"key":"6155_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1177\/0049124104268644","volume":"33","author":"KP Burnham","year":"2004","unstructured":"Burnham KP, Anderson DR (2004) Multimodel inference: understanding AIC and BIC in model selection. Sociol Methods Res 33:261\u2013304","journal-title":"Sociol Methods Res"},{"key":"6155_CR21","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1093\/ndt\/gfq018","volume":"25","author":"G Tripepi","year":"2010","unstructured":"Tripepi G, Jager KJ, Dekker FW, Zoccali C (2010) Statistical methods for the assessment of prognostic biomarkers (part I): discrimination. Nephrol Dial Transpl 25:1399\u20131401","journal-title":"Nephrol Dial Transpl"},{"key":"6155_CR22","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/sim.4154","volume":"30","author":"H Uno","year":"2011","unstructured":"Uno H, Cai T, Pencina MJ et al (2011) On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med 30:1105\u20131117","journal-title":"Stat Med"},{"key":"6155_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.10.006","volume":"133","author":"J Jelicic","year":"2019","unstructured":"Jelicic J, Larsen TS, Maksimovic M, Trajkovic G (2019) Available prognostic models for risk stratification of diffuse large B cell lymphoma patients: a systematic review. Crit Rev Oncol Hematol 133:1\u201316. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.10.006","journal-title":"Crit Rev Oncol Hematol"},{"key":"6155_CR24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M et al (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20\u2009+\u2009B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9:105\u2013116","journal-title":"Lancet Oncol"},{"key":"6155_CR25","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Sehn LH, Rademaker AW et al (2014) An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123:837\u2013842","journal-title":"Blood"},{"key":"6155_CR26","doi-asserted-by":"publisher","unstructured":"Zhong Q, Chen H, Chen D et al (2023) Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study. Ann Hematol 103:211\u2013226. https:\/\/doi.org\/10.1007\/s00277-023-05491-0. (PT - Article)","DOI":"10.1007\/s00277-023-05491-0"},{"key":"6155_CR27","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/blood.2019002729","volume":"135","author":"AS Ruppert","year":"2020","unstructured":"Ruppert AS, Dixon JG, Salles G et al (2020) International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood 135:2041\u20132048","journal-title":"Blood"},{"key":"6155_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/S41408-023-00930-7","volume":"13","author":"J Jelicic","year":"2023","unstructured":"Jelicic J, Juul-Jensen K, Bukumiric Z et al (2023) Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models. Blood Cancer J 13:157. https:\/\/doi.org\/10.1038\/S41408-023-00930-7","journal-title":"Blood Cancer J"},{"key":"6155_CR29","doi-asserted-by":"publisher","first-page":"e383","DOI":"10.1038\/bcj.2015.111","volume":"6","author":"T Kobayashi","year":"2016","unstructured":"Kobayashi T, Kuroda J, Yokota I et al (2016) The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era. Blood Cancer J 6:e383\u2013e383","journal-title":"Blood Cancer J"},{"key":"6155_CR30","first-page":"5325","volume":"15","author":"P Zhao","year":"2018","unstructured":"Zhao P, Zang L, Zhang X et al (2018) Novel prognostic scoring system for diffuse large B-cell lymphoma. Oncol Lett 15:5325\u20135332","journal-title":"Oncol Lett"},{"key":"6155_CR31","first-page":"2610","volume":"15","author":"Y Li","year":"2023","unstructured":"Li Y, Zhu Y, Duan X (2023) Prognostic value of multiple immune inflammatory markers in diffuse large B-cell lymphoma. Am J Transl Res 15:2610\u20132621","journal-title":"Am J Transl Res"},{"key":"6155_CR32","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/cam4.1271","volume":"7","author":"J Biccler","year":"2018","unstructured":"Biccler J, Eloranta S, de Nully Brown P et al (2018) Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI. Cancer Med 7:114\u2013122","journal-title":"Cancer Med"},{"key":"6155_CR33","doi-asserted-by":"publisher","unstructured":"Jelicic J, Larsen TS, Andjelic B et al (2024) Should we use nomograms for risk predictions in diffuse large B cell lymphoma patients? A systematic review. Crit Rev Oncol Hematol 196. https:\/\/doi.org\/10.1016\/J.CRITREVONC.2024.104293","DOI":"10.1016\/J.CRITREVONC.2024.104293"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06155-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-06155-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-06155-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T11:09:00Z","timestamp":1739358540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-06155-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":33,"alternative-id":["6155"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-06155-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JJ has received travel support from AstraZeneca and Roche. PB has served on advisory boards for Roche, Abbvie, and SERB. TSL has served on advisory boards\/consultancy for Roche, Novartis, Gilead, and BMS. TSL received a research Grant from Genentech and travel support from Roche. Other authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in accordance with the principles of the Declaration of Helsinki. The Advisory Board for Clinical Quality Development Program (RKKP) (project number 21\/27006) has granted approval for conducting this registry-based study, ensuring total anonymity of patients. Further details can be found in the Declaration on passing personal data covered by \u00a7\u00a010, a subsection of the Data Protection Act, 1 and 2\u2019, . Therefore, informed consent from patients was not obtained.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}